Management of prostate cancer in older patients: Updated recommendations of a working group of the International Society of Geriatric Oncology

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages

  Droz, Jean Pierre ^a   Aapro, Matti ^b   Balducci, Lodovico ^c   Boyle, Helen ^a   Van den Broeck, Thomas ^d   Cathcart, Paul ^e   Dickinson, Louise ^f   Efstathiou, Eleni ^g   Emberton, Mark ^f   Fitzpatrick, John M ^h   Heidenreich, Axel ⁱ   Hughes, Simon ^j   Joniau, Steven ^d   Kattan, Michael ^k   Mottet, Nicolas ^l   Oudard, Stéphane ^m   Payne, Heather ⁿ   Saad, Fred ^o   Sugihara, Toru ^k  

^a UNIVERSITÉ LYON 1   (France)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^m HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁿ UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^o CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; RADIUM CHLORIDE RA 223; ZOLEDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ASSESSMENT; COMORBIDITY; DAILY LIFE ACTIVITY; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL DISSOCIATION; GERIATRIC ASSESSMENT; GERIATRIC CARE; HEALTH CARE PLANNING; HEALTH STATUS; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL DECISION MAKING; MINIMALLY INVASIVE PROCEDURE; NUTRITIONAL STATUS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; AGE; AGED; COMPARATIVE STUDY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; ELDERLY CARE; INTERNATIONAL COOPERATION; MEDICAL SOCIETY; MORTALITY; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; STANDARDS; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY; WATCHFUL WAITING;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; GERIATRIC ASSESSMENT; HEALTH SERVICES FOR THE AGED; HUMANS; INTERNATIONAL COOPERATION; MALE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RISK ASSESSMENT; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84904873737     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70018-X     Document Type: Review

References (79)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
3. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013, 190:429-438.
4. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013, 24:1141-1162. for the Panel Members and the European Society for Medical Oncology.
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline): prostate cancer National Comprehensive Cancer Network, (accessed Oct 14, 2013). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
6. Heidenreich A, Bastian PJ, Bellmut J, et al. Guidelines on prostate cancer (accessed Oct 14, 2013). http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf.
7. Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010, 73:68-91.
8. Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010, 106:462-469.
9. Heidenreich A, Abrahamsson PA, Artibani W, et al. Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 2013, 64:347-354.
10. Walter LC, Covinsky KE Cancer screening in elderly patients: a framework for individualized decision making. JAMA 2001, 285:2750-2756.
11. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011, 29:1335-1341.
12. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55:241-252. for the Task Force on CGA of the International Society of Geriatric Oncology.
13. Baitar A, Van Fraeyenhove F, Vandebroek A, et al. Evaluation of the Groningen Frailty Indicator and the G8 questionnaire as screening tools for frailty in older patients with cancer. J Geriatr Oncol 2013, 4:32-38.
14. Luciani A, Ascione G, Bertuzzi C, et al. Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol 2010, 28:2046-2050.
15. Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: The ONCODAGE project. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 9001.
16. Bellera CA, Rainfray M, Mathoulin-Pélissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 2012, 23:2166-2172.
17. Comprehensive Geriatric Assessment (CGA) in oncological patients. Updated July 20, 2011 International Society of Geriatric Oncology (SIOG), (accessed Oct 3, 2013). http://siog.org/images/SIOG_documents/cga_practice_guideline_wildiers_jul2011.pdf.
18. Blanc-Bisson C, Fonck M, Rainfray M, Soubeyran P, Bourdel-Marchasson I Undernutrition in elderly patients with cancer: target for diagnosis and intervention. Crit Rev Oncol Hematol 2008, 67:243-254.
19. Terret C, Zulian G, Droz JP Statements on the interdependence between the oncologist and the geriatrician in geriatric oncology. Crit Rev Oncol Hematol 2004, 52:127-133.
20. O'Brien BA, Cohen RJ, Ryan A, Sengupta S, Mills J A new preoperative nomogram to predict minimal prostate cancer: accuracy and error rates compared to other tools to select patients for active surveillance. J Urol 2011, 186:1811-1817.
21. Briganti A, Joniau S, Gontero P, et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur Urol 2012, 61:584-592.
22. Walz J, Gallina A, Saad F, et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 2007, 25:3576-3581.
23. Briganti A, Gallina A, Suardi N, et al. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med 2010, 7:2521-2531.
24. Abdollah F, Sun M, Suardi N, et al. A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. BJU Int 2013, 111:905-913.
25. Valdagni R, Kattan MW, Rancati T, et al. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys 2012, 82:1957-1966.
26. Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. Eur Urol 2013, 63:88-96.
27. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007, 177:2106-2131. for the AUA Prostate Cancer Clinical Guideline Update Panel.
28. Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD Do older men benefit from curative therapy of localized prostate cancer?. J Clin Oncol 2003, 21:3318-3327.
29. Sun L, Caire AA, Robertson CN, et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009, 182:2242-2248.
30. Brassell SA, Rice KR, Parker PM, et al. Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol 2011, 185:132-137.
31. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012, 118:3062-3070.
32. Houterman S, Janssen-Heijnen ML, Verheij CD, Kil PJ, van den Berg HA, Coebergh JW Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study. Prostate Cancer Prostatic Dis 2006, 9:179-184.
33. Briganti A, Spahn M, Joniau S, et al. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis. Eur Urol 2013, 63:693-701. for the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).
34. Abdollah F, Sun M, Thuret R, et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006. Eur Urol 2011, 59:88-95.
35. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213. for the Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group.
36. Mitchell CR, Boorjian SA, Umbreit EC, Rangel LJ, Carlson RE, Karnes RJ 20-year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. BJU Int 2012, 110:1709-1713.
37. Alibhai SM, Leach M, Tomlinson G, et al. 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst 2005, 97:1525-1532.
38. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 2004, 172:2227-2231.
39. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012, 13:43-54.
40. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008, 26:585-591.
41. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011, 12:451-459.
42. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
43. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11:1066-1073.
44. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
45. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008, 299:289-295.
46. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
47. Chen AB, D'Amico AV, Neville BA, Earle CC Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol 2006, 24:5298-5304.
48. Ward JF, Jones JS Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int 2012, 109:1648-1654.
49. Ahmed HU, Hindley RG, Dickinson L, et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 2012, 13:622-632.
50. de la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol 2010, 24:775-780.
51. Studer UE, Collette L, Whelan P, et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008, 53:941-949. for the EORTC Genitourinary Group.
52. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
53. Keating NL, O'Malley AJ, Smith MR Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
54. Ehdaie B, Atoria CL, Gupta A, et al. Androgen deprivation and thromboembolic events in men with prostate cancer. Cancer 2012, 118:3397-3406.
55. Nguyen PL, Chen MH, Beckman JA, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012, 82:1411-1416.
56. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012, 367:895-903.
57. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003, 21:2163-2172.
58. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717. the SPCG-4 Investigators.
59. Albertsen PC, Hanley JA, Fine J 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
60. Aapro M, Saad F Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 2012, 4:85-101.
61. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512. for the TAX 327 Investigators.
62. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26:242-245.
63. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
64. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 2009, 55:1368-1375.
65. Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, et al. 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013, 14:117-124. for the PROSTY study group.
66. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154. for the TROPIC Investigators.
67. Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol 2013, 24:2402-2408. for the TROPIC Investigators.
68. Ozguroglu M, Oudard S, Sartor AO, et al. G-CSF prophylaxis reduces the occurance of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastic castration-resistant prostate cancer. Proc Am Soc Clin Oncol 2011, 29. abstr 144.
69. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011, 29:3457-3465.
70. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 2012, 118:3377-3386.
71. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005. for the COU-AA-301 Investigators.
72. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992. for the COU-AA-301 Investigators.
73. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148. for the COU-AA-302 Investigators.
74. Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012, 13:1210-1217.
75. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197. for the AFFIRM Investigators.
76. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223. for the ALSYMPCA Investigators.
77. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882. for the Zoledronic Acid Prostate Cancer Study Group.
78. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
79. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422. for the IMPACT Study Investigators.